The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers
Open accessPublished version of a preprint
Abstract
TP53 mutations are common in lung cancers of smokers, with high prevalence of G:C-to-T:A transversions generally interpreted as mutagen fingerprints of tobacco smoke. In this study, TP53 (exons 5-9) and KRAS (codon 12) were analyzed in primary lung tumors of never (n = 40), former (n = 27), and current smokers (n = 64; mainly heavy smokers). Expression of p53, cyclooxygenase-2 (Cox-2), and nitrotyrosine (N-Tyr), a marker of protein damage by nitric oxide, were analyzed by immunohistochemistry. TP53 mutations were detected in 47.5% never, 55.6% former, and 77.4% current smokers. The relative risk for mutation increased with tobacco consumption (Plinear trend < 0.0001). G:C-to-T:A transversions (P = 0.06, current versus never smokers) and A:T-to-G:C transitions (P = 0.03, former versus never smokers) were consistently associated with smoking. In contrast, G:C-to-A:T transitions were associated with never smoking (P = 0.02). About half of mutations in current smokers fell within a particular domain of p53 protein, suggesting a common structural effect. KRAS mutations, detected in 20 of 131 (15.3%) cases, were rare in squamous cell carcinoma compared with adenocarcinoma [relative risk (RR), 0.2; 95% confidence interval (95% CI), 0.07-1] and were more frequent in former smokers than in other categories. No significant differences in Cox-2 expression were found between ever and never smokers. However, high levels of N-Tyr were more common in never than ever smokers (RR, 10; 95% CI, 1.6-50). These results support the notion that lung tumorigenesis proceeds through different molecular mechanisms according to smoking status. In never smokers, accumulation of N-Tyr suggests an etiology involving severe inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike other clinically actionable genomic alterations found in NSCLCs (such as EGFR and ALK aberrations), KRAS mutations, particularly KRASG12C and KRASG12V, are strongly associated with smoking29–31.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans
Carter, R. L. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.1.98-b · Cited by 3,455
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,107
Self-citationBiochemistry, Biology, and Carcinogenicity of Tobacco-Specific N -Nitrosamines
Hecht, S. S. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980005y · Cited by 1,074
Molecular Damage in the Bronchial Epithelium of Current and Former Smokers
Wistuba, I. I., Virmani, A. K., Gazdar, A. F., Lam, S. C., LeRiche, J., Behrens, C., Fong, K. M., Samet, J. M., Srivastava, S., & Minna, J. D. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.18.1366 · Cited by 487
Hainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375
Self-citationClinical significance of ras oncogene activation in human lung cancer
Therapy, E. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90536-7 · Cited by 361
Research works printed but not linked: 1
- Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435–51. · DOI
Cited by
Sorted by citations
Items 201–272 of 272
Eyzaguirre, A., Buck, E. A., Iwata, K. K., Haley, J. D., & Miglarese, M. R. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0093-6 · Cited by 5
Analysis of the Target Genes of Transcription Factor ZNF536 in Lung Adenocarcinoma
Xu, X. (2019) · International Conference on Bioinformatics and Biomedical Technology (ICBBT) · doi:10.1145/3340074.3340095 · Cited by 4
Malignant Mesothelioma: Mechanism of Carcinogenesis
Kane, A. B., Jean, D., Knuutila, S., & Jaurand, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2825-0_17 · Cited by 4
Lin, K., Lin, J., Huang, Z., Fu, J., Yi, Q., Cai, J., Khan, M. B., Yuan, Y., & Bu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881493 · Cited by 3
Immuntherapie von Kopf-Hals-Karzinomen
Schuler, P. J., Hoffmann, T. K., Gauler, T. C., Bergmann, C., Brandau, S., & Lang, S. (2012) · HNO · doi:10.1007/s00106-012-2635-6 · Cited by 3
Proteomics-Based Disease Biomarkers
Misek, D. E., Kondo, T., & Duncan, M. W. (2011) · International Journal of Proteomics · doi:10.1155/2011/894618 · Cited by 3
Li, T., Liu, J., Zhou, Y., Huang, S., Wang, D., Chen, J., Fu, Y., & He, P. (2024) · Cancer Medicine · doi:10.1002/cam4.7227 · Cited by 2
Stražišar, M., Rott, T., & Glavač, D. (2008) · Disease Markers · doi:10.1155/2008/232743 · Cited by 3
Yin, L. G., Zou, Z., Zhao, H., Zhang, C., Shen, J. G., Liu, Q., Qi, M., & Xue, Z. (2014) · Molecular Biology · doi:10.1134/s0026893314050185 · Cited by 3
Takanashi, Y., Tajima, S., Hayakawa, T., Neyatani, H., & Funai, K. (2015) · PubMed Central · Cited by 3
Erasmus, J. J., McAdams, H. P., & Rossi, S. E. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-05375-4.50026-4 · Cited by 3
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Antibodies as Cancer Immunotherapy
Mahalingam, D., & Curiel, T. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_11 · Cited by 2
Loss of TP53-DNA interaction induced by p.C135R in lung cancer
Aranda, M., González-Nilo, F. D., Riadi, G., Díaz, V., Perez, J., Martel‐Planche, G., Hainaut, P. L., & Mimbacas, A. (2007) · Oncology Reports · doi:10.3892/or.18.5.1213 · Cited by 2
Self-citationA review on tobacco and its effect on health
Lalruatfela, B. (2019) · Science Vision · doi:10.33493/scivis.19.01.04 · Cited by 2
Cvetković, G., Plavec, G. I., Tomić, I., Ilić, V. L., Magić, Z., Tatomirović, Ž., Novković, D., Milić, R., & Karlicic, V. (2009) · Vojnosanitetski pregled · doi:10.2298/vsp0902149c · Cited by 2
Carcinogenic Polycyclic Aromatic Hydrocarbons
Marques, C. F., Murray, J. R., & Penning, T. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00087-5 · Cited by 2
Biochemical Pathways in Cancer
Breuer, E.-K. Y., Murph, M. M., & Craven, R. J. (2012) · Biochemistry Research International · doi:10.1155/2012/268504 · Cited by 1
Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
Allemann, A., & Gautschi, O. P. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-72 · Cited by 1
Holowatyj, A. N., Liu, L., Munro, H. M., Perkins-Smith, J. J., Han, X., Kolitsopoulos, F. M., Shrubsole, M. J., Lipworth, L. P., Russo, L., & Zheng, W. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1161 · Cited by 1
Davies, J., & Menzies, G. E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1654434 · Cited by 1
Functional significance of miR-218 in lung cancer
Aggarwal, D., Thyagarajan‐Sahu, A., & Sahu, R. P. (2026) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2025.108 · Cited by 1
Pradhan, B., Mishra, P., Dash, P., Niharika, Baral, T., Mishra, J., Chakraborty, S., Nandi, P., & Patra, S. K. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.04.294 · Cited by 1
p53: Point Mutations, SNPs and Cancer
Fang, M., Simeonova, I., & Toledo, F. (2012) · InTech eBooks · doi:10.5772/33715 · Cited by 1
EFFECTS OF LOW-DOSE GAMMA RADIATION IN A MURINE MODEL OF BENZO[A]PYRENE-INDUCED LUNG CANCER
Bruce, V. R. (2015) · UNM’s Digital Repository (University of New Mexico) · Cited by 1
US and Global Epidemiology and Incidence Rates of Lung Cancer
DeBiasi, E. M. (2023) · Respiratory medicine · doi:10.1007/978-3-031-38412-7_1 · Cited by 1
Erdem, H. B., Alay, M. T., Özdemir, Z. T., Çevik, E., Ateş, Ö., Karaçin, C., Şahin, İ., Doğan, M., & Bahsi, T. (2023) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2023.111847 · Cited by 1
Liang, H., Deng, J., Luo, T., Luo, H., Li, F., Wu, K., & Lin, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41006 · Cited by 1
Role of TP53 Mutations in Cancer (An Overview)
Toledo, F. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_5 · Cited by 1
Molecular Biology of Lung Cancer as the Basis for Targeted Therapy
Gautschi, O. P., Mack, P. C., Heighway, J., Gumerlock, P. H., & Gandara, D. R. (2007) · CRC Press eBooks · doi:10.3109/9781420020359.001 · Cited by 1
Deng, J., Liang, H., Luo, T. L., Luo, H., Wu, X., Ye, Y., Wang, S., Li, F., Wu, K., & Lin, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.366 · Cited by 1
Epidemiology of Lung Cancer in Women
Wu, A. H., & Seow, A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00079-0 · Cited by 1
Eberhard, D. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_20 · Cited by 1
Panorama of Chromosomal Instability in Lung CancerPreprint
Yang, Y., Zhong, X., Phillips, W., Wei, Z., Hoang, P. H., Wirth, C., Yang, S., Leduc, C., Baine, M. K., Travis, W. D., et al. (2025) · medRxiv · doi:10.1101/2025.09.09.25335109 · Cited by 1
Self-citationLungekreft hos røykere og aldri-røykere
Helland, Å., & Brustugun, O. T. (2009) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.08.0652
Microarrays in Lung Cancer Research: From Comparative Analyses to Verified Findings
Ruosaari, S. (2008) · Työväentutkimus Vuosikirja
Franklin, W. A. (2008) · Lung Cancer · doi:10.1002/9780470696330.ch8
DNA Repair Capacity and the Risk of Head and Neck Cancer
Szaumkessel, M., Gawcki, W., & Szyfter, K. (2012) · InTech eBooks · doi:10.5772/31555
Molecular epidemiology of lung cancer in the Liverpool lung project (LLP) cohort
Souza, N. D. (2015) · University of Liverpool · doi:10.17638/02006199
Um, S., Kim, H., Kwon, O. J., Han, J., & Shim, Y. M. (2008) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2008.65.6.487
The Importance of Isoprenylation and Nf1 Deficiency in K-RAS-induced Cancer
Sjogren, A.-K. M. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Environmental factors and p53 mutation spectrum in lung cancer
Bessö, A. (2006) · Figshare
Caractérisation moléculaire de tumeurs pulmonaires radon-induites chez le rat
Bastide, K., & BERNAUDIN, J.-F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Cancer broncho-pulmonaire chez le non-fumeur
Planchard, D., & Soria, J. (2011) · Springer eBooks · doi:10.1007/978-2-287-99041-0_12
Lívia, A. (2012) · Pesci Egyetemi Archivum (University of Pécs)
Cáncer de pulmón en no fumadores
Palma, I. V., Quadrelli, S., Lamot, S., Hernández, M., Lyons, G., & Venditti, J. (2010) · Redalyc (Universidad Autónoma del Estado de México)
The Gender-Specific Aspects of Lung Cancer
Toonkel, R. L., & Powell, C. A. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00023-x
Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).
Arrieta, O. G., Cardona, A. F., Gallo, A., Bramuglia, G. F., Campos-Parra, A. D., Serrano, S., Poleri, C., Amorín, E., Kirchuk, R., Cuello, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.e21155
Bastide, K. (2009)
Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy
Jebsen, N. L., Scarlett, S., Magnúsdóttir, B. T., & Gjertsen, B. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_22
Environmental Tobacco Smoke, Genetic Susceptibility, and Lung Cancer among Never Smokers
Kim, C. H. (2016) · eScholarship (California Digital Library)
Lacoste, S. (2007) · Corpus Université Laval (Université Laval)
Erasmus, J. J., Stewart, D. J., Komaki, R. R., & Swisher, S. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2232-1.00006-1
KRAS: The Art of Understanding a Complex Gene
Velasco, W. V., Ramos-Castaneda, M. A., Clowers, M. J., Deng, S., & Moghaddam, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00003-2
Oncogenic variants guiding treatment in thoracic malignancies
Meng, P. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.160074057
Phylomedicine of mutational processes in somatic cancer cell populationsPreprint
Miura, S., Vu, T., Choi, J., & Kumar, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.02.438268
Arcila, M. E., Chang, J. C., & Tafe, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_6
Erasmus, J. J., Nguyen, Q., Stewart, D. J., & Swisher, S. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69538-1.00007-0
Liang, H., Deng, J., Luo, T., Luo, H., Wu, X., Ye, Y., Wang, S., Li, F., Wu, K., & Lin, C. (2021) · Research Square · doi:10.21203/rs.3.rs-533843/v2
Liang, H., Deng, J., Luo, T., Luo, H., Wu, X., Ye, Y., Wang, S., Li, F., Wu, K., & Lin, C. (2021) · Research Square · doi:10.21203/rs.3.rs-533843/v1
Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine
Jebsen, N. L., Ktoridou-Valen, I., & Gjertsen, B. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_33
Zheng, J., Liu, Z.-Q., Chen, G., Zhao, Y., Yang, Y., Fang, W., & Zhang, L. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161556
Voropaeva, E. N., Churkina, M. I., Баширзаде, К. А., Pospelova, T. I., Ageeva, Т. А., & Maksimov, V. N. (2022) · JOURNAL of SIBERIAN MEDICAL SCIENCES · doi:10.31549/2542-1174-2022-6-3-72-89
Gautam, S., Sangma, M. A., Rana, S., Khetrapal, S., Kapur, S., & Jairajpuri, Z. S. (2023) · Journal of Laboratory Physicians · doi:10.1055/s-0043-1772680
Qin, X., Wu, J., Qin, F., Zheng, Y., Chen, J., Liu, Z., Tan, J. W., Cai, W., He, S., Jian, B., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-1003
Kiso, M., Urabe, Y., Ito, M., Masuda, K., Boda, T., Kotachi, T., Hata, K., Yorita, N., Nagasaki, N., Abduwali, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12737738
Menzies, G. E., Prior, I. A., Brancale, A., Reed, S. H., & Lewis, P. D. (2021) · Figshare · doi:10.6084/m9.figshare.16620664
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
Benhabiles, H. (2017) · theses.fr (ABES) · doi:10.70675/b3efeca2z5bbfz48b9z949ezefd67a3e0613
Nooreen, Z., Armo, R., Johri, H. V., Babu, R. H., Nehra, P., & Gasmi, A. (2026) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/0118756921432491260401063552
Oncogene Driver Status Modulates TP53 Prognostic Impact in Advanced NSCLCPreprint
Pan, M., Jiang, C., Song, J., Kudrimoti, S., Aredo, J. V., Wakelee, H. A., Neal, J. W., Zhao, J., Kamgarhaghighi, Y., Achacoso, N. S., et al. (2026) · medRxiv · doi:10.64898/2026.09.04.26362258
Metadata
- Authors
- Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P.
- Affiliations
- 1IARC, Lyon, France;
- Russian Cancer Research Center NN Blokhin (RU)
- Centre international de recherche sur le cancer (FR)
- 4Department of Cellular Pathology, The Medical School, University of Birmingham, Egbaston, Birmingham, United Kingdom
- ORCID
- Venue
- Cancer Research
- Published
- 2005-06-15
- Volume
- 65
- Issue
- 12
- Pages
- 5076-5083
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2149459560
- Cited by
- 273
- References
- 54
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 15 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 9 · 2014: 11 · 2013: 14 · 2012: 27
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Commission (IC15-CT96-0313)
- National Institutes of Health (5k01es000358-03)
- National Institute of Environmental Health Sciences (K01‐ES00358)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- TP53 mutation, KRAS mutation, lung cancer, smoking, mutation patterns, G:C to T:A transversions, cyclooxygenase-2, nitrotyrosine, nitric oxide, inflammation, never smokers, former smokers, squamous cell carcinoma, adenocarcinoma, lung carcinogenesis
- MeSH terms
- Aged, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Membrane Proteins, Middle Aged, Mutation, Prostaglandin-Endoperoxide Synthases, Genes, ras, Smoking, Tyrosine, Genes, p53, Tumor Suppressor Protein p53, Cyclooxygenase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
